An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cerus Corporation (CERS) announced its participation in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference. Vivek Jayaraman, COO, will present on February 16 at 9:00 a.m. EST, while CFO Kevin Green will participate on February 18 at 12:00 p.m. EST. The events are for BTIG clients, and webcasts can be accessed via Cerus' investor relations webpage. Cerus focuses on safeguarding the blood supply globally, offering the INTERCEPT Blood System, which has CE and FDA approvals for pathogen reduction.
Positive
None.
Negative
None.
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference.
On Wednesday, February 16th at 9:00 a.m. EST, Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference. BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
On Friday, February 18th at 12:00 p.m. EST, Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 11th Annual SVB Leerink Global Healthcare Conference. To listen to the webcast, please visit the investor relations section of Cerus’ website at: ir.cerus.com.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Matt Notarianni – Senior Director, Investor Relations
Cerus Corporation 925-288-6137
Source: Cerus Corporation
FAQ
What is the date and time of Cerus Corporation's presentation at the BTIG Conference?
Cerus Corporation will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 9:00 a.m. EST.
Who will represent Cerus Corporation at the SVB Leerink Global Healthcare Conference?
Kevin Green, the Chief Financial Officer of Cerus Corporation, will represent the company at the SVB Leerink Global Healthcare Conference on February 18 at 12:00 p.m. EST.
How can I access the webcast for Cerus Corporation's presentation?
The webcast for Cerus Corporation's presentation can be accessed through the investor relations section of their website at ir.cerus.com.
What is Cerus Corporation's main focus?
Cerus Corporation is dedicated to safeguarding the world's blood supply and aims to be the leading global blood products company.
What technology does Cerus Corporation offer for blood safety?
Cerus Corporation offers the INTERCEPT Blood System, which provides pathogen reduction for blood components with CE Mark and FDA approval.
